Stratasys and CollPlant Biotechnologies have announced a joint development and commercialisation agreement to collaborate on the development of a solution to bio-fabrication human tissues and organs using Stratasys’ P3 technology-based bioprinter and CollPlant’s rh-Collagen-based bioinks.
The first project focuses on the development of an industrial-scale solution for CollPlant's regenerative breast implants programme.
Stratasys is a specialist in polymer 3D printing solutions. CollPlant is a regenerative and aesthetics medicine company developing technologies and products based on its plant-based collagen for tissue regeneration and organ manufacturing.
The new bioprinter, based on Stratasys’ precise P3 3D printing technology in combination with CollPlant's flagship bioinks, will enable the production of CollPlant’s breast implants, which are being designed to regenerate an individual’s natural breast tissue without eliciting immune response, providing an alternative for both aesthetic and reconstructive procedures.
Currently the global breast implant market is estimated to be $2.6 billion, while breast reconstruction and augmentation procedures represent the second most common plastic surgery procedure performed worldwide today. The most common breast augmentation or reconstruction procedures today are based on synthetic silicone breast implantations, an artificial substitution for natural regenerated tissue with risks of complications.
Under the agreement, both companies have agreed to cross-promote each other’s bioprinting products. Stratasys’s bioprinter will be offered to customers together with CollPlant’s bioinks, and similarly Stratasys’ bioprinter will be offered to CollPlant’s business partners and customers.
“Through this partnership with CollPlant, we have an important opportunity to transform healthcare with bioprinting to improve the lives of patients undergoing breast augmentation or reconstruction procedures,” said Stratasys CEO Dr. Yoav Zeif. “This agreement is well-aligned with our strategy to deliver complete solutions for high-growth industry applications with our ecosystem of partners, and the production scale and precision 3D printing capabilities of Stratasys’ P3 Programmable Photopolymerisation technology are a particularly strong fit for bioprinting applications. We believe that partnering with CollPlant will enable us to accelerate the industrialisation of bioprinting for regenerative medicine, and we look forward to collaborating towards the successful commercialisation of CollPlant’s novel regenerative breast implants and beyond.”
Yehiel Tal, CEO of CollPlant, commented, “Stratasys is leading in additive manufacturing and we are excited to collaborate with them on this transformative initiative. The P3 technology allows printing with high resolution and process control, and we believe that the combined, pioneering technologies of both companies will streamline the development and production process so that we have the most efficient means to produce our regenerative breast implants and other potential tissues and organs. We believe that our rhCollagen-based regenerative implant has the potential to overcome the challenges of existing breast procedures that use silicone implants or autologous fat tissue transfer.”
In January 2023, CollPlant announced that it successfully completed a large-animal study for its 3D bioprinted regenerative breast implants. The preclinical study demonstrated progressive stages of tissue regeneration after three months, as highlighted by the formation of maturing connective tissue and neovascular networks within the implants, with no adverse events reported. Based on these positive results, CollPlant is planning to initiate a follow-up, large-animal study in the second half of 2023 using commercial-size implants to support subsequent human studies and future product commercialisation.